The next catalyst.
The whole picture.

IVAInventiva S.A.lanifibranor

Conference presentation

CGEMCULLINAN THERAPEUTICS, INC.Velinotamig (GR-1803)

Partner-led: Genrix Bio · Region not stated · Expected Phase 1 data

FATEFATE THERAPEUTICS INCFT839

Conference presentation

NKTXNkarta, Inc.NKX019

Phase 1/2 data

VIRVir Biotechnology, Inc.Elebsiran and tobevibart

Phase 2 data

VIRVir Biotechnology, Inc.Elebsiran and tobevibart

Phase 2 data

FATEFATE THERAPEUTICS INCFT819

Phase 2 data

NKTXNkarta, Inc.NKX019

Phase 1/2 data

NKTXNkarta, Inc.NKX019

Phase 1/2 data

RADXRadiopharm Theranostics LimitedRAD101

Interim clinical data

BTAIBioXcel Therapeutics, Inc.BXCL501 / IGALMI

U.S. sNDA decision

CYTKCYTOKINETICS, INCORPORATEDMYQORZO (aficamten)

U.S. sNDA decision

SMMTSummit Therapeutics Inc.ivonescimab (SMT112)

U.S. BLA decision

CAPRCAPRICOR THERAPEUTICS, INC.CAP-1002 (deramiocel)

U.S. BLA decision

SVRASavara IncMOLBREEVI™

U.S. BLA decision

U.S. NDA decision

BBIOBridgeBio Pharma, Inc.BBP-418

Regulatory

NUVLNUVALENT, INC.Neladalkib (NVL-655)

U.S. NDA decision

VRTXVERTEX PHARMACEUTICALS INC / MApovetacicept

U.S. BLA decision